secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001171843-24-005922
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Therapeutics completes sale of Arthrosurface for $10M; plans to divest Parcus Medical
--------------------------------------------------------------------------------

- Sold Arthrosurface to Phoenix Brio for $7M note plus up to $3M contingent consideration based on sales performance.
- Announced intention to sell Parcus Medical sports medicine business as part of strategic review.
- Focus shifts to core hyaluronic acid (HA) products and Regenerative Solutions, targeting $4B global market.
- Piper Sandler serving as exclusive financial advisor for both the Arthrosurface sale and potential Parcus divestiture.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184324005922/0001171843-24-005922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184324005922/f8k_103024.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-005922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer